AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsitePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier PagePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier PagePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier PagePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier PagePCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
More Information Supplier PagePCI-34051 is a specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms.
More Information Supplier PagePCI-34051 is a specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms.
More Information Supplier PagePCI-34051 is a specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms.
More Information Supplier PagePCI-34051 is a specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms.
More Information Supplier PagePCI-34051 is a specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms.
More Information Supplier PagePD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PagePD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PagePD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PagePD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PagePD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
More Information Supplier PagePD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
More Information Supplier PagePD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
More Information Supplier PagePD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
More Information Supplier PagePD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.
More Information Supplier PagePD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.
More Information Supplier PagePD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.
More Information Supplier PagePD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.
More Information Supplier PagePD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.
More Information Supplier PagePD 150606 is a cell-permeable, non-competitive, selective, non-peptide Ca2+ dependent calpain inhibitor for calpain-1 and for calpain-2 directed towards the Ca2+ binding sites of calpain.
More Information Supplier PagePD 150606 is a cell-permeable, non-competitive, selective, non-peptide Ca2+ dependent calpain inhibitor for calpain-1 and for calpain-2 directed towards the Ca2+ binding sites of calpain.
More Information Supplier PagePD 150606 is a cell-permeable, non-competitive, selective, non-peptide Ca2+ dependent calpain inhibitor for calpain-1 and for calpain-2 directed towards the Ca2+ binding sites of calpain.
More Information Supplier PagePD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 ??M for ??-Calpain, about 20-fold selectivity over m-calpain.
More Information Supplier PagePD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 ??M for ??-Calpain, about 20-fold selectivity over m-calpain.
More Information Supplier PagePD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 ??M for ??-Calpain, about 20-fold selectivity over m-calpain.
More Information Supplier PagePD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 ??M for ??-Calpain, about 20-fold selectivity over m-calpain.
More Information Supplier PagePD166793 is a cell-permeable compound that strongly inhibits MMP (matrix metalloproteinase) -2 , -3, and -13, and weakly inhibits AMP deaminase, MMP-1, -7, -9, and -14.
More Information Supplier PagePD166793 is a cell-permeable compound that strongly inhibits MMP (matrix metalloproteinase) -2 , -3, and -13, and weakly inhibits AMP deaminase, MMP-1, -7, -9, and -14.
More Information Supplier PagePD166793 is a cell-permeable compound that strongly inhibits MMP (matrix metalloproteinase) -2 , -3, and -13, and weakly inhibits AMP deaminase, MMP-1, -7, -9, and -14.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1).
More Information Supplier PagePD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1).
More Information Supplier PagePD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1).
More Information Supplier PagePD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
More Information Supplier PagePD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
More Information Supplier PagePD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
More Information Supplier PagePD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
More Information Supplier PagePD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
More Information Supplier PagePD153035 is an extremely potent and specific inhibitor of the tyrosine kinase activity of EGFR.
More Information Supplier Page
